Price Chart
Key Statistics
Market Cap(EOD)258.25M
Enterprise Value279.36M
P/E Ratio (TTM)-2.41
P/B Ratio (TTM)8.09
P/S Ratio (TTM)0.00
Earnings Yield (TTM)-41.51%
ROE (TTM)-159.97%
ROIC (TTM)-136.35%
Net Profit Margin (TTM)N/A
Dividend Yield (TTM)N/A
Payout Ratio (TTM)N/A
Debt/Equity (TTM)1.48
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.